Gamma Knife Market Research Report 2024 with Market Share Analysis, Trends and Forecast

Gamma knife is an advanced radiation therapy for the treatment of cancer in adults and children. Gamma knife is not really a knife; it is a beam of highly focused gamma rays, to precisely cut or destroy the tumor or damaged cells, generally in the brain, causing little or no damage to the surrounding normal cells. Gamma knife technology is used to treat medium brain tumors, trigeminal neuralgia, epilepsy, nerve disorders that causes chronic pain, abnormal blood vessel formations called arteriovenous malformations, and other neurological conditions. Patients with serious diseases can be treated with the help of this technology which is a noninvasive procedure and get cured in a few days with no long hospital stay, returning to normal life and activity promptly. Typically, gamma knife treatment is completed in a few hours with little or no side effects. According to Leksell Gamma Knife Society, gamma knife technology is universally preferred and no other radiosurgery system has greater clinical acceptance as gamma knife. Gamma knife radiosurgery is performed in leading hospitals around the world, with more than 70,000 patients treated every year. To treat with gamma knife technology the surgeon neither requires to make an incision in the scalp, nor an opening in the skull.

Browse Market Research Report @ http://www.transparencymarketresearch.com/gamma-knife-market.html

The gamma knife market can be segmented by disease indication and geography. Based on disease indication, the market is classified into cancer, arteriovenous malformation (AVM), trigeminal neuralgia, essential tremor and others (epilepsy, Parkinson’s disease etc.). Cancer holds the dominant share of the gamma knife market by disease indication, and its increasing prevalence is expected to boost the overall market. There are over 100 types of cancer. According to WHO, about 16% of the world population die because of cancer. In 2015, 8.8 million people died of cancer. This is expected to be the prominent driver for the gamma knife market.

Geographically, the gamma knife market is classified into five regions, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America has the leading market share followed by the other developed region, Europe. The U.S. accounts for a major share of the global market. According to the American Cancer Society, in 2016, about 1,685,210 new cancer cases were diagnosed. Advanced technologies, high awareness levels, and high purchasing power in North America influenced the gamma knife technology market expansion significantly. However, the same factor of affordability has restrained the markets in developing regions. Despite this, the gamma knife market in Asia Pacific has shown significant increase in growth rate. Rising population, increase in disposable income, increase in the geriatric population, and increase in awareness levels are some key factors driving the Asia Pacific market. Due to these factors, the Asian market is observing a large number of new entrants compared to developed regions.

Other factors that drive the gamma knife market are increasing prevalence of various types of cancer, increasing preference toward non- and minimally-invasive procedures, high adoption and acceptance in developed markets, high success rate of gamma knife procedure, innovations and developments in technology, and comprehensive health insurance cover for radio surgery procedures. The market is also experiencing certain restraints such as stiff competition among existing players, high cost of the procedure, low equipment availability, and lack of awareness about gamma knife therapy among the rural population in developing and underdeveloped economies.

Fill the form for an exclusive sample of this report @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=19592

The major players in the gamma knife market include Elekta, Varian Medical Systems, Huiheng Medical, Inc., Nordion Inc., ET Medical Group, and American Shared Hospital Services.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Cell-free Protein Expression Market is Expected to Show Staggering Growth by 2024

Cell-free protein expression, also called in vitro protein synthesis, involves the production of the desired recombinant proteins in cell lysates without using cell culture or living cells. Cell lysates produced via the breakdown and use of cellular components (eukaryotic or bacterial cells of humans or insects). Cell-free protein expression is carried out using different cell extracts such as those of E. coli (prokaryotic), rabbit reticulocytes, wheat germs eukaryotes), and insect cells. This system has many significant advantages over protein expression in living cells including the shorter duration of the process, expression of toxic proteins, isotopic labeling of proteins, optimization of protein complexes, incorporation of non-natural amino acids, optimization of protein production, and cost-effectiveness. Cell-free protein expression also allows the co-expression of multiple proteins and is easily employed for automation.

Browse Market Research Report @ http://www.transparencymarketresearch.com/cell-free-protein-expression-market.html

The global cell-free protein expression market is divided into the following product types on the basis of lysates used: mammalian, E. coli, wheat germs, and insect membrane. Among these, E. coli cell lysates are highly used. In terms of the expression mode, CFPS are categorized into the continuous and batch modes. The three major end-users of CFPS systems are the pharmaceutical & biotechnological industry, contract research institutes, and academic & research institutes, of which pharmaceutical companies are dominant, followed by contract research institutes.

The global CFPS market is driven by the key advantages of this system over in vivo protein synthesis such as the shorter duration required to receive the desired recombinant proteins, advanced applications in enzyme engineering, protein purification, and modification. Other factors projected to propel the market during the forecast period include the increasing demand for protein synthesis, rising activity of outsourcing pharmaceutical and biotechnological companies, and the growing number of research and academic institutes. New developments such as Protein Synthesis Using Recombinant Elements (PURE) offer opportunities for specialized applications such as in vitro protein evolution, protein micro-arrays, and protein labelling. The high cost of CFPS & reagents and low protein production rates are anticipated to restrict the global CFPS market.

Based on geography, global CFPS market is distributed over North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. North America dominates the market owing to the high expenditure on R&D activities and increasing demand for protein synthesis in the region. Europe and APAC are likely to display high growth rates during the forecast period as a result of the surge in R&D, biopharmaceutical companies, and demand for recombinant proteins.

Fill the form for an exclusive sample of this report @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=19595

Key players operating in the global CFPS market include New England Biolabs, Inc., TAKARA BIO INC., Thermo Fisher Scientific Inc., Promega Corporation., CellFree Sciences Co., biotechrabbit GmbH, Bioneer Corporation, Jena Bioscience GmbH, and Cube Biotech GmbH etc. Among these, Thermo Fisher Scientific Inc., biotechrabbit GmbH, and New England Biolabs, Inc. are the leaders. The New England Biolabs, Inc. has developed the technology PURE for CFPS and is promoting its use and application across the globe.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Calcitonin Salmon Market: Industry Insights with Key Company’s Profiles - Forecast to 2026

Calcitonin, also called thyrocalcitonin, is a linear polypeptide hormone produced in human thyroid glands by parafollicular cells. In fish, birds, and other non-mammalian animals, calcitonin is produced by cells of ultimobranchial body. Calcitonin lowers the levels of calcium and phosphate in blood and promotes the bone formation. Calcitonin inhibits the bone removal cells called osteoclasts and simultaneously promotes bone formation cells called osteoblasts. The potency of calcitonin salmon per mg is greater and has longer duration of action than calcitonin produced by mammalian origin. Calcitonin salmon is produced either by synthetic processes or by microbial processes using recombinant DNA technology. Calcitonin salmon is available in two forms: injection and nasal. Miacalcin and Fortical are commonly available brands for calcitonin salmon. Calcitonin salmon is used for indications such as osteoporosis, hypercalcemia, Paget’s disease of bone, and other bone related diseases.

Browse Market Research Report @ http://www.transparencymarketresearch.com/calcitonin-salmon-market.html

The global calcitonin salmon market is driven by increasing number of osteoporosis patients globally. According to the International Osteoporosis Foundation, over 8.9 million people suffer from osteoporosis globally each year. Osteoporosis is more dominant in women than men and is common in geriatric population. The International Osteoporosis Foundation study reveals that over 200 million women are affected by osteoporosis globally. The FDA advisory committee has recommended to prevent use of calcitonin salmon for the treatment of postmenstrual osteoporosis in women as there exists a potential risk of cancer development. Moreover, calcitonin salmon is used as second line of treatment for osteoporosis. Side effects of calcitonin salmon are likely to be key restraints of the global market. Large number of people are not aware about having osteoporosis until they have first fracture and also Paget’s disease is not common in people. These factors hamper the growth of the calcitonin salmon market. Easy availability of other medications for the first line treatment of osteoporosis and related diseases is likely to restrain the market. The FDA advisory committee has suggested to companies developing new calcitonin salmon products to prove its effectiveness in reducing bone fractures. This is expected to boost the market.

The global calcitonin salmon market has been segmented based on route of administration and type of indication. Calcitonin salmon can be administered through injection or by nasal spray. The calcitonin nasal spray is indicated for patients for whom alternative treatments are not suitable. Calcitonin injections are used for the treatment of Paget’s disease of bone and hypercalcemia. It can be administered through subcutaneous, intramuscular, and intranasal routes. Calcitonin salmon is used for the treatment of osteoporosis, Paget's disease, and hypercalcemia.

Geographically, the global calcitonin salmon market has been segmented into five regions: North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. Over 75 million people are estimated to be affected by osteoporosis in the U.S., Europe, and Japan. This highlights the growth opportunity in these regions. Prevalence of osteoporosis is higher in Middle East & Africa than in countries in the West. This is expected to propel the calcitonin salmon market in this region. Increasing geriatric population with bone related diseases is likely to fuel the growth of the market in Asia Pacific during the forecast period.

Fill the form for an exclusive sample of this report @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=19730

Key players in the calcitonin salmon market include Novartis AG, Apotex, Inc., Upsher-Smith Laboratories, Inc., Alkem Laboratories Ltd., Torrent Pharmaceuticals Limited, Glenmark Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., and United Biotech (P) Limited. Novartis AG, Upsher-Smith Laboratorie, Inc., and Torrent Pharmaceuticals are the leading players in the global calcitonin salmon market.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Bone Marrow Transplant Market - Latest Innovations and Upcoming Key Events in the industry by 2026

Global Bone Marrow Transplant Market: Overview 

The world bone marrow transplant market could rest its growth in demand on the rife prevalence of disorders such as anemia, non-Hodgkin and Hodgkin lymphoma, thalassemia, and leukemia, besides the common bone marrow diseases. No doubt, bone marrow is a critical constituent of the body’s immune and circulatory systems which are involved in the production of lymphocytes and red blood cells. A successful bone marrow transplant can save a life, which itself could be a major driver of the global market.

Browse Market Research Report @ http://www.transparencymarketresearch.com/bone-marrow-transplant-market.html

The international bone marrow transplant market could be segmented on parameters such as treatment procedure, disease indication, and end user. Coupled with a detailed evaluation of the global market, the analysts are seasoned enough to offer a study based on deep segmentation, even to the possible micro levels.

The publication is a fine guideline for industry players to sustain a competitive edge in the global bone marrow transplant market with the most reliable data made available at their disposal. With an absolute blend of trends analysis and quantitative forecasting, the authors have offered a forward-looking insight for multitudinous decision makers.

Global Bone Marrow Transplant Market: Trends and Opportunities

A bone marrow transplant is the last resort commonly recommended by physicians in the cases of fatal bone marrow diseases and bone or skin cancer. Thus, it could be easily predicted that the spiraling occurrence of such diseases, typically blood cancer, could be a paramount facet propelling the growth of the worldwide bone marrow transplant market. The malfunctioning of bone marrow can prove to be devilishly detrimental to the health of a human body. In this regard, the ascending ubiquity of unwholesome diets, inactive way of living, and alcohol or smoking addiction could furnish a rising demand for bone marrow transplant.

There is a climbing trend witnessed on the part of bone marrow transplant where patients are becoming increasingly confident about the procedure. This could be ascribed to the improving prognosis of the medical condition of patients on the back of concerted research and development in bone marrow transplant. As a result, the performance of the global bone marrow transplant market is anticipated to enhance remarkably as the process keeps getting unchallenging and technologically sophisticated. One of the reasons for this improved performance could be extensive research in the employment and storage of donated bone marrow and their logistical and biological factors.

Global Bone Marrow Transplant Market: Geographical Analysis 

Although North America is expected to demonstrate a promising growth in the coming years, Europe could possess the undying potential to clench a dominating share in the international bone marrow transplant market. With the presence of an elevating number of advanced healthcare centers, the Europe market is foreseen to be all set for a tangible demand growth. Most healthcare systems have introduced bone marrow transplant in their offerings coupled with state-of-the-art public facilities.

Even in developed regions, the bone marrow market could become sluggish due to the meagerness of donors and exorbitant expense of the procedure, also concerning post-operative care and round-the-clock monitoring. Despite the attenuating restraints, key players can expect lucrative market opportunities to leap up from the hopeful awareness about bone marrow transplant in emerging nations. Moreover, optimistic reimbursement options are prognosticated to add to the rise of opportunities in the face of a few market constraints.

Fill the form for an exclusive sample of this report @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11237

Global Bone Marrow Transplant Market: Competitive Landscape 

Out of the commanding market players, AllCells LLC, Merck Millipore Corp., STEMCELL Technologies, Sanofi-Aventis LLC, and Lonza Group Ltd. are expected to make the cut with cutting-edge bone marrow transplant equipment added to their portfolio. The report holds the potential to offer a comprehensive analysis of the future strategies, important developments, and supply chain trends adopted by the dominant companies operating in the global bone marrow transplant market.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Huber Needle Market - Outlook and Opportunity Analysis 2016 – 2026

Global Huber Needle Market: Overview 

With a significant rise in the number of chronic diseases across the globe and the robust development of the healthcare infrastructure are some of the key factors propelling the global huber needle market. The research study offers a detailed overview of the global market and throws light on the factors that are likely to encourage the growth of the market. The key segmentation of the global market, along with the primary applications and technological developments have been included in the research study. An in-depth analysis of the competitive landscape of the global huber needle market has been given to provide a strong understanding to readers and market players.

Browse Market Research Report @ http://www.transparencymarketresearch.com/huber-needle-market.html

Global Huber Needle Market: Drivers and Restraints 

The tremendous rise in several deadly ailments such as chronic renal diseases, cancer, and obesity across the globe is one of the major factors that is predicted to fuel the growth of the global huber needle market in the next few years. In addition, stringent government regulations regarding the reduction in needle stick injuries and ensure patient safety are some of the other important aspects expected to accelerate the growth of the overall market in the forecast period.

On the other hand, the high cost of products and the lack of product innovations are projected to restrict the growth of the global huber needle market in the near future. In addition, the risk of contamination is likely to hamper the growth of the market. Nonetheless, the emergence of favorable reimbursement policies of vascular access needles is estimated to generate lucrative and promising opportunities for prominent players operating in the global huber needle market.

Global Huber Needle Market: Region-wise Outlook 

The global huber needle market has been categorized on the basis of geography in order to offer a clear understanding of the market. The key regional segments of the market are the Middle East and Africa, Latin America, North America, Asia Pacific, and Europe. As per the research study, Europe and North America are projected to hold a substantial share of the global huber needle market. The high growth of these two regions can be attributed to the presence of a large number of players and the availability of advanced healthcare infrastructure.

Furthermore, the Asia Pacific and Latin America huber needle markets are expected to witness a healthy growth rate in the next few years. The research study offers a detailed overview of every regional segment in order to guide the new entrants in making effective business decisions in the near future. Moreover, the share and size of each segment, along with the expected growth rate have been included in the scope of the research study.

Key Players Mentioned in the Research Report are: 

The global market for huber needles is growing at a healthy pace and is likely to witness a significant rise in the number of players in the global market. The leading players in the global market are making remarkable efforts to enhance their product portfolio in order to attract a large number of consumers across the globe. In addition, the technological advancements in this field are projected to encourage the growth of the overall market in the next few years.

Fill the form for an exclusive sample of this report @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=19904

Some of the leading players operating in the huber needle market across the globe are B. Braun Medical Inc., Smiths Medical, Baxter International Inc., NIPRO Medical Corporations, C.R. Bard, Thiebaud S.A.S., AngioDynamics, Inc., Exel International, Inc., and Vygon S.A. To offer a clear understanding of the market, the research report offers an in-depth analysis of the competitive landscape and highlights the business strategies and policies that have been adopted by them to sustain in the global market.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Transfusion Diagnostics Market Present Scenario and the Growth Prospects 2024

Blood transfusion is a process of receiving blood products or blood into the circulatory system intravenously. Blood transfusion is used in different medical conditions for replacement of lost component in the blood. Earlier blood transfusion included whole blood; however, modern medical methods can use only a component of blood for transfusion. Blood transfusion is among the most common procedures used for patients in hospitals. Hence, it becomes imperative that clinicians have knowledge about the appropriate administration of blood products, along with the symptoms, signs, and transfusion reaction management. Different blood products that can be transfused in the human body are red blood cells, platelets, plasma, albumin, and immunoglobulin preparations.

Browse Market Research Report @ http://www.transparencymarketresearch.com/transfusion-diagnostics-market.html

The blood transfusion process is as follows: blood sample is taken and sent to hospital laboratory where tests are performed to ensure that the donor blood is compatible with patient's blood. This process is called cross-matching. Risks associated with blood transfusion are viral infections, allergic reactions, fever, hemolytic reactions, and iron overload. Everything possible should be done to reduce these risks during blood transfusion. Hence, before blood transfusion, several steps are taken to ensure the quality of blood products, compatibility, and safety to the recipient. A definite diagnosis is required for both the donor and recipient blood. Red blood cells are the most common blood products to be transfused. One of the transfusion diagnostics incudes molecular blood group diagnostics. Molecular blood group diagnostic enables safer blood preservation and on-demand supply for patients who have antibodies against clinically relevant, rare or weak antigens. Blood group serology is another blood transfusion diagnostic used to avoid side effects caused due to administration of incorrect blood preservatives or immunizations.

Based on type, the transfusion diagnostics market can be segmented into instruments, reagents and others. In terms of application, the market can be segmented into blood grouping, disease screening, and others. Based on distribution channel, the market can be segmented into hospitals, laboratories, blood banks, plasma fractionation facilities, military blood banks, and others. Blood banks and hospitals are the major segments of the transfusion diagnostics market.

Increasing prevalence of diseases which require complete blood transfusion is one of the major drivers of the transfusion diagnostics market. Rising number of accidents due to road rash or other reasons which lead to blood loss is also likely to propel the market. Another factor driving the transfusion diagnostics market is the rising emergency situations for blood transfusions during surgical blood loss. Rising number of diseases due to improper blood transfusion without diagnosis of blood also fuels the growth of the transfusion diagnostics market. Alternative treatments and better techniques for blood transfusion are the major restraints of the transfusion diagnostics market. More advanced, efficient, and reliable transfusion diagnostic techniques are expected to create significant opportunities in the market.

Geographically, the transfusion diagnostics market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for the largest share of the blood transfusion diagnostics market owing to increasing health care awareness and technological advancement in the region. Europe is the second largest market for blood transfusion diagnostics due to large geriatric population in the region. Asia Pacific is the fastest growing market for blood transfusion diagnostics due to increasing adoption of improved health care technologies, emerging health care infrastructure, and rising accidents, diseases, and other emergency situations which require blood transfusion.

For more information on this report, fill the form @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=20588

Major players in the blood transfusion diagnostics market include Ortho Clinical Diagnostics, Beckman Coulter, Quotient Limited, Novartis AG, Abbott Diagnostics, Diagast, Becton, Dickinson and Company, Immucor, Inc., BAG Health Care, DiaSorin, Fujirebio Diagnostics, Inc., Grifols, S.A., Hologic/Gen-Probe, Biokit, Bio-Rad Laboratories, and Quidel Corporation.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Syringe Filters Market Explores New Growth Opportunities By 2016 – 2024

Syringe filter, commonly known as wheel filter, is fitted with a cartridge at the end of a syringe. Syringe filter works with the help of a lock fitting which is used to provide a secure fitting to the syringe. The use of a needle is optimal and can be fitted to the end of the syringe filter during usage. The syringe filter generally consists of a plastic wrapped with a membrane like substance, which serves as a filter. The fluid used to be purified can be cleaned by drawing it through the syringe filters and forcing the unfiltered fluid out. Syringe filters can be used to filter solid drugs prior to injection. The filters get rid of many impurities present in drugs in the form of fungal spores, bacteria, or fillers. However, usage of pills and other drugs in liquid form for administering into the body can bring a profit to the pharmaceutical industry.

Browse Market Research Report @ http://www.transparencymarketresearch.com/syringe-filters-market.html

High prevalence of diseases, such as cardiovascular diseases, neurological diseases, cancer, and other infectious diseases, rise in patient awareness, and growth in research and development initiatives are the driving factors for the syringe filters market. Presence of fungal spores and bactericidal in the semipermeable membrane of syringe filters is expected to hamper the syringe filters market growth during the forecast period.

The global syringe filters market has been segmented based on type, application, end-user, and geography. In terms of type, the market for syringe filter is classified into cellulose acetate syringe filter, glass fiber syringe filter, nitrocellulose polymer syringe filter, nylon syringe filter, polyethersulfone polymer syringe filter, and others. In terms of application, the market is classified into pharmaceutical, environmental, biotechnology, food/beverage, and agricultural. Infectious disease and impure transfer of pyrogen is likely to show growth in market segment. In terms of end-user, the market is classified into diagnostic laboratories, life sciences and research & development, hospitals, and others. In terms of geography, the market is distributed over North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

Geographically, North America dominates the global syringe filters market due to increase in drug purification agency and high demand for HPLC systems in pharmaceutical industries and biotechnology industries. Automated filtration systems and hard-to-filter samples are expected to drive the syringe filters market in North America. Europe is the second leading market for syringe filters as there are favorable government policies regarding health care infrastructure. The market in Asia Pacific is expected to grow at a higher rate due to change in lifestyle, rise in awareness among patients, and increase in per capita expenditure. In addition, economic growth is supporting the health care infrastructure improvement in developing countries such as India and China by expanding the different pharmaceutical and biotechnological research units.

For more information on this report, fill the form  @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=20423

The major players operating in the global syringe market include GE Healthcare, Sterlitech Corporation, Pall Corporation, and Fisher Scientific (Thermo Fisher Scientific).

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Syphilis Treatment Market Research Report Forecast Upto 2024

Syphilis is one of the sexually transmitted infections (STI) caused by the Treponema pallidum bacteria. It can lead to complications in the long term, if not diagnosed effectively. Syphilis is a global health concern due to increasing incidence. According to the World Health Organization (WHO), an estimated 36 million cases of syphilis were reported in 2013 globally, with over 11 million new cases occurring annually. Additionally, around 90% of the syphilis cases are prevalent in developing countries, with similar trends observed in developed nations as well. The increasing syphilis cases are attributed to the growing rate of anonymous sex, sex with multiple partners, sex under the influence of several drugs, and increasing number of unprotected sex. Moreover, it is gaining prominence among pregnant women, which can further lead to congenital abnormalities such as stillbirth, abortions, and other abnormalities in pregnancy.

Browse Market Research Report @ http://www.transparencymarketresearch.com/syphilis-treatment-market.html

According to the Centers for Disease Control and Prevention, there are no home remedies or over-the-counter drugs that will cure syphilis, but syphilis is easy to cure in its early stages. A single intramuscular injection of long acting Benzathine penicillin G (2.4 million units administered intramuscularly) will cure a person who has primary, secondary, or early latent syphilis. Three doses of long acting Benzathine penicillin G (2.4 million units administered intramuscularly) at weekly intervals is recommended for individuals with late latent syphilis or latent syphilis of unknown duration. Treatment will kill the syphilis bacterium and prevent further damage, but it will not repair damage already done. In 2013, over 56,400 cases of syphilis were reported in the U.S. The rate of women infected with syphilis has been declining in the U.S., but the rate among men, particularly homosexual men, has been rising.

There are four stages of syphilis: primary, secondary, latent, and tertiary. Syphilis is infectious in the first two stages. When it is in the unknown, or in latent stage, syphilis remains active, but often it shows no symptoms and is even not contagious to others. Tertiary syphilis is the most damaging to human health. Primary as well as secondary syphilis are often treated with a penicillin injection. Antibiotic penicillin is one of the most extensively used antibiotics and is effective in the treatment of syphilis. Penicillin allergic people are treated with a different antibiotic, such as ceftriaxone azithromycin, or doxycycline.

Increasing prevalence of syphilis globally is expected to drive the growth of the syphilis treatment market. However, certain challenges faced by the market include insufficient infrastructure provisions in labs, equipment, and supplies, lack of trained laboratory personnel in the developing regions such as countries in West Africa and stigma associated with voluntary testing. These factors are likely to restrain market growth.

Geographically, Europe and North America are the two major regional markets for syphilis treatment, as awareness about the disease is high in Europe. Presently, Latin America and Middle East & Africa are lucrative markets for investment. According to the WHO, syphilis prevalence was highest in countries in Africa. As stated by the World Health Organization (WHO) in December 2015, over 1 million sexually transmitted infections are acquired every day globally. Each year, there are 357 million new infections, with 1 in 4 sexually transmitted infections: chlamydia (131 million), gonorrhoea (78 million), syphilis (5.6 million), and trichomoniasis (143 million).

For more information on this report, fill the form  @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=20345

Pfizer, Inc. is the only major player in the syphilis treatment market. Bicillin L-A is the only currently approved penicillin G benzathine product indicated for the treatment of syphilis manufactured by Pfizer, Inc.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Authorized Generics Market: Segmentation, Global Market Regional Outlook 2024

A generic drug is a duplicate copy of original branded drug, which has same dosage form, active pharma ingredients (API), strength, route of administration, and also same intended use as the branded one. Regulatory authorities and governments have mandated that an authorized generic drug has to medicinally correspond to the branded drug and sanctioned as an Abbreviated New Drug Application (ANDA) by the Food and Drug Administration (FDA). An authorized generic is the branded company’s individual product, but repackaged and marketed as generic drug either via subsidiary or third party. These are already approved as a New Drug Application by the FDA, only they are promoted via private label. The authorized generics market grew rapidly in the past few years as these provide consumers with branded quality drugs at generic prices. Presently, there is a growing trend of original maker giving approvals to a subsidiary or a private label distribution company to sell its brand name drug as a generic drug at a subsequently low price.

Browse Market Research Report @ http://www.transparencymarketresearch.com/authorized-generics-market.html

An example of authorized generic drug is Azithromycin Pak which is sold under by the company name Greenstone. Pfizer’s original branded drug Z-pak was approved by the FDA. Before patent expiry of Z-pak, Pfizer allowed Greenstone to sell Z-pak using authorized generic name Azithromycin Pak. Greenstone is a wholly owned subsidiary of Pfizer.

The global authorized generics market is expected to witness strong growth. Authorized generic drugs are priced at significantly discounted rate i.e. 50% to 70% as compared to branded counterparts. Additionally, many of the popular branded drugs of pharma companies are losing patent protection rights, which is also termed as patent cliffs. This would pave the way for entry of new complex generics in the market. These factors are likely to drive the authorized generics market in the near future. Other factors driving the market are health care plans by governments across the world, rapidly increasing cost of branded drugs, and aging populations. On the other hand, possibility of side effects, and lack of regulatory awareness about products and quality management are factors likely to restrain the global authorized generics market.

The global authorized generics market can be classified based on product type, application, end-user, and region.

In terms of product type, the global authorized generics market can be segmented into biosimilars, simple generic, super generic, and others. Based on applications the market can be classified into cardiovascular, anti-infective, anti-arthritis, central nervous system, anti-cancer, respiratory, and others.

Geographically, the global authorized generics market can be divided into North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. North America accounted for the largest share of the market, primarily due to technological advancements, rise in demand for generic drugs, increase in overall cost of branded drugs, and presence of key players. Europe held a significant share of the market attributed to advancements in generic drugs, rise in various types of cancer, and blood related disorders. Asia Pacific, however, has been exhibiting high growth rate on account of growing demand for generic drugs, rise in geriatric population, increase in disposable income, and government initiatives to support generic drugs. Rapidly rising population in the region has increased demand for better health care and induced both private and government players to meet the demand. Developing economies such as India and China have also made a significant contribution to the rise of the global authorized generics market by focusing on establishing a better health care infrastructure.

For more information on this report, fill the form  @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=20609

Key players in the market are Teva Pharmaceuticals, Sandoz, Allergan, Mylan, Sun Pharmaceuticals, and STADA Arzneimittel. Other prominent vendors in the market are Abbott, Amgen, Apotex, Aspen, AstraZeneca, Aurobindo Pharma, Baxter, Berlin-Chemie, Biocon, Biogen, Boehringer Ingelheim, Celltrion, Cipla, Coherus Biosciences, Dr. Reddy's Laboratories, Daiichi Sankyo, Eli Lilly and Company, Emcure Pharmaceuticals, Eurofarma Laboratories, Gedeon Richter, Gilead Sciences, and GlaxoSmithKline.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Latest Research Report on Hemostasis Diagnostics Market: Trends and Opportunities 2024

Hemostasis, the body’s normal physiological response to stop bleeding after a vascular injury, is a key procedure in the first line of action attempted post an injury, by the body itself or by medical respondents. Preventing significant loss of blood is vital for the survival of a patient, making hemostasis the focus of widespread research and study. Owing to the critical nature of the procedure, the hemostasis products market has gained a prominent position in the field of medicine and health care.

Browse Market Research Report @ http://www.transparencymarketresearch.com/hemostasis-diagnostics-market.html

Rising global prevalence of hemophilia A and B, the most common inherited bleeding disorders, significant surge in a variety of surgeries and trauma patients, and increasing use of recombinant products are the factors likely to drive the hemostasis diagnostics market in the near future. The rapid rate of introduction of cost effective and biodegradable products in the global market is also aiding the growth of the market. Growth across cost-sensitive emerging markets is essentially due to easy availability of cost-effective products. However, saturation of the global hemostasis market and high cost structures of advanced hemostasis products are hampering the growth of the market.

The hemostasis diagnostics market has been segmented based on product type, end-user, and region. Based on product type, the hemostasis diagnostics market has been segmented into analyzers, reagents, and consumables. Analyzers can be further segmented into fully automated analyzers and semi-automated analyzers. Accuracy of hematology analyzers has been enhanced by automation of systems and use of cell surface marker labels. Automated analyzers function by sampling the blood and classifying cell populations by quantification and description. This may be carried out using both electrical and optical techniques. Sophisticated hematology blood cell analyzers are enabling precise disease diagnosis at an early stage. Fully-automated systems compact in size, easy to use, providing networking solutions, and efficient data management have increased adoption of hematology analyzers. In terms of end-user, the hemostasis diagnostics market has been segmented into hospitals, clinical testing laboratories, research & academic institutes, and others.

Hematology instruments and reagents continue to maintain strong position in the health care industry. Market players are making significant investment in product development to offer user-friendly, more sophisticated, efficient, and accurate analyzers to meet the demands of hospitals and clinics. Automated systems play a crucial role in transfusion medicines and facilitate screening of blood donors as well as quality control of blood products.

Geographically, the hemostasis diagnostics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is likely to dominate the global hemostasis diagnostics market owing to the rising installed instrument base leading to higher sales of reagents and support services in the U.S. Beckman Coulter is the market leader in hematology analyzers in the U.S.; however, it faces continuous competition from Sysmex products. The hemostasis diagnostics market in Europe is expected to be driven by steady rise in geriatric population which would boost demand for hemostasis. The vast and continuously rising set of under-served population suffering from bleeding disorders such as hemophilia, especially across developing economies such as India, is expected to boost the adoption of hemostasis products in Asia Pacific. Emerging markets such as India, China, and Brazil are registering significant growth due to increasing population, rise in health care expenditure and higher affordability, economic development, and improving technical capabilities by these countries.

For more information on this report, fill the form  @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1503

Major players operating in the hemostasis diagnostics market include Abbott Laboratories, Becton, Dickinson and Company, Grifols, S.A, Alere, Inc., F. Hoffmann-La Roche AG, Siemens Healthineers, and Beckman Coulter, Inc.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Pneumoperitoneum Market Research Report Forecast to 2016 - 2024

Pneumoperitoneum is referred as abnormal gas within the peritoneal cavity. Peritoneum is a complex, large serous membrane which forms closed sac in abdominal cavity. The pneumoperitoneum is often an indication of illness. It is necessary to be diagnosed correctly because errors in diagnosis can lead to various pseudopneumoperitoneum. Perforated abdominal viscus is the most common cause of pneumoperitoneum. The causes of pneumoperitoneum differ from children to adults. The common cause of pneumoperitoneum in adults are peptic ulcer disease, ischemic bowel, bowel obstruction, malignancy, necrotizing enterocolitis, inflammatory bowel disease (e.g. megacolon), appendicitis, diverticulitis, peritoneal dialysis, mechanical perforation such as colonoscopy, trauma, iatrogenic, etc. In females, it is also caused by vaginal aspiration, insufflation, douching, sudden squatting, postpartum exercises, and etc. The causes of pneumoperitoneum in children are perforation and iatrogenic effect. Perforated hollow viscus includes the most common cause i.e., necrotizing enterocolitis (NEC), and others such as Hirschsprung disease, peptic ulcer disease, intestinal atresia or web, meconium ileus in cystic fibrosis, etc. The iatrogenic effect consists of rectal thermometer, enema, post intubation or mechanical ventilation.

Obtain Report Details @ http://www.transparencymarketresearch.com/pneumoperitoneum-market.html

The common symptoms of pneumoperitoneum are abdominal pain, vomiting, constipation, fever, hypotension, tachypnea, and diarrhea. Different signs of pneumoperitoneum are cupola/saddlebag/mustache sign, lucent liver sign, football sign, Silver's sign/falciform ligament sign, inverted V sign, telltale triangle sign, urachus sign, Rigler's sign, and others. Pneumoperitoneum is usually detected by radiography. An erect chest X-ray and supine abdominal X-ray are used to detect pneumoperitoneum. The erect chest X-ray is the most sensitive plain radiograph for pneumoperitoneum detection and there are several signs that may be used for detecting free gas in abdominal X-ray.

The pneumoperitoneum market has been divided based on detection type, end-user, and region. In terms of detection type, the market has been segmented into erect chest X-ray (plain radiograph) and supine abdominal X-ray (abdominal radiograph). The erect chest x-ray is the most sensitive X-ray for detection of free intraperitoneal gas. The signs of gas such as subdiaphragmatic free gas, and cupola sign can be detected with this method. Abdominal X-ray (radiograph) can detect various pneumoperitoneum signs. Bowel related signs (Rigler's sign, telltale triangle sign) where the air outlining on both sides of bowel wall, peritoneal ligament related signs (football sign, urachus sign, and others), and right upper quadrant signs (Morison's pouch sign, lucent liver sign, etc.) can be detected through abdominal X-ray (radiograph). Usage of specific detection techniques is likely to boost the growth the market in the near future. Rising gastric and abdominal diseases are also driving the global market.

Based on end-user, the pneumoperitoneum market has been segmented into hospitals, ambulatory surgical centers, diagnostic centers, and others. Hospitals hold the major share of the pneumoperitoneum market, because of rising incidence of abdominal problems such as inflammatory bowel disease (e.g. megacolon), and mechanical perforation such as colonoscopy, trauma, and iatrogenic effect. Preference for diagnostic centers for radiography imaging is also expected to increase in the near future.

In terms of region, the global pneumoperitoneum market has been segmented into North America, Europe, Asia Pacific, and Rest of the world. North America accounted for the largest share of the pneumoperitoneum market due to high health care awareness, prevalence of abdominal disorders, and technological advancements in the region. Europe held the second largest share attributed to increasing geriatric population. However, countries in Asia are expected to be the fastest growing markets due to growing awareness, gradual adoption of improved technologies, emerging health care infrastructure, increased purchasing power of hospitals, and rising population.

For more information on this report, fill the form  @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=20321

Key players in the pneumoperitoneum market are Fujifilm Holdings Corporation, GE Healthcare, Hologic, Inc., and Philips Healthcare, among others. Regional players are also contributing significantly to the growth of the pneumoperitoneum market.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Lab Informatics Market 2026 Trends, Challenges and Growth Drivers Analysis

Global Lab Informatics Market: Snapshot

The rise of the global lab informatics market is attributable to both, the increasing rate of diagnoses and soaring technological advancements that have introduced improved tools. Furthermore, the widening application of lab informatics solutions in industries such as the food and beverage, chemical, research and development, life sciences, and contract research is expected to have a positive impact on the global market. The phenomenal accuracy and efficiency of results offered by the systems available in the global lab informatics market are projected to benefit growth prospects in the coming years.

Obtain Report Details @ http://www.transparencymarketresearch.com/lab-informatics-market.html

Transparency Market Research has compiled a thorough research report that discusses the global lab informatics market in complete detail. The research report highlights the market drivers, opportunities, threats, and weaknesses impacting the overall market. Furthermore, the document also includes SWOT analysis and Porter’s five forces analysis that gives a granular view of the ever-changing market dynamics. The publication is aimed at guiding its readers to formulate strategic, profitable, and well-informed decisions to further their businesses.

Global Lab Informatics Market: Segmentation

The global market offers products such as laboratory information management systems (LIMS), electronic lab notebooks (ELN), scientific data management systems, enterprise content management (ECM), and chromatography data systems. The report indicates that LIMS is expected to lead the global market in the coming years as the system truly offers a wide range of features such as sample lifecycle, reporting, security and system administration, stability study, instrument, schedule, and analytic workflow. These features have definitely brought in value to the product, which has translated into effective delivery of results.

Integration of IT in lab informatics has augmented the demand for cloud-based services in the global market over the past few years. The ease of real-time data entry and remote access have won cloud-based delivery mode a significant consumer base. It’s most likely that this segment will lead the global market leaving behind the on-premise delivery mode segment.

Global Lab Informatics Market: Regional Outlook

Currently, the global lab informatics market is divided into regions such as Asia Pacific, Europe, North America, the Middle East and Africa, and Latin America. The report indicates that North America will dominate the global market in the coming years. The indomitable stance of this regional market will be due to the strong presence of the leading giants in North America, higher level of awareness about diseases and diagnosing them, and well-equipped end users for LIMS. It has been observed that increasing funding for research and development activities in the pharmaceutical and biotech industry of North America is also projected to boost the market in the coming years.

Currently, Asia Pacific is also presenting the lab informatics market with incredible growth opportunities. The region’s increasing need to improve its research and development facilities, emerging economies with flourishing industry, and several unmet medical needs are expected to favor Asia Pacific lab informatics market in the near future.

For more information on this report, fill the form  @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=20249

Key Players Mentioned in the Report are:

Some of the leading players in the global lab informatics market are Thermo Fisher Scientific, Inc., LabVantage Solutions, Inc., LabWare, Inc., LLC, Core Informatics, LabLynx, Inc., Abbott Informatics, PerkinElmer, Inc., ID Business Solutions Ltd., Waters Corporation, and Agilent Technologies, Inc.  These players are fervently focused on advancing their research laboratories with the best of technical knowledge, IT integration, and affordable pricing to lure in larger consumer bases.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Ophthalmic Lasers Market Development Status and Outlook 2024

Ophthalmic lasers find applications in the treatment of various ophthalmic diseases that cause blindness, such as glaucoma, cataract, diabetic retinopathy, and age related macular degeneration (AMD), among others. Various types of lasers are employed for the treatment of these diseases, including diode lasers, Nd:YAG lasers, argon lasers and SLT, among others.

Obtain Report Details @ http://www.transparencymarketresearch.com/ophthalmic-lasers-market.html

As per a new research study by Transparency Market Research (TMR), the global ophthalmic lasers market demonstrates a moderately competitive landscape and is led by Alcon, Carl Zeiss, Lumenis Ltd., Ellex Medical Laser Ltd., and Quantel Group. These players, however, hold only a marginal share of this market. In 2015, they collectively accounted for a share of nearly 35% in the overall market.

Over the forthcoming years, the market is likely to experience intense competition due to the entry of large pharmaceutical drugmakers into the market for surgical devices through strategic acquisitions.

According to the research report, the opportunity in the global market for ophthalmic lasers was worth US$0.97 bn in 2015. Rising at a CAGR of 4.60% during the period from 2016 to 2024, the market is likely to increase to US$1.44 bn by the end of the forecast period. Ophthalmic clinics have surfaced as the key end users of ophthalmic lasers across the world and are likely to remain so over the coming years.

North America to Retain Leadership as Asia Pacific Offers Lucrative Opportunities

In terms of geographies, the research report classifies the worldwide market for ophthalmic lasers is classified into Europe, Asia Pacific, North America, Latin America, and the Middle East and Africa. In 2016, North America led this market with a share of more than 40%, where the presence of a large pool of established players played the central role.

Over the next few years, with the help of the increasing research and development activities, availability of a well-established regulatory framework for the timely approval of the products, and the presence of a state-of-art healthcare infrastructure, the North America market for ophthalmic lasers is anticipated to continue its leading streak. Asia Pacific, on the other hand, is projected to surface as the most lucrative market for ophthalmic lasers across the world in the near future. China is expected to lead the Asia Pacific market for ophthalmic lasers in the years to come.

The Middle East and Africa and Latin America are also expected to register steady growth in their respective markets for ophthalmic lasers over the forthcoming years, thanks to the remarkable rise in medical tourism and the cost efficiency of laser eye surgeries in these regions. The Latin America market for ophthalmic lasers is projected to be led by Mexico and Columbia while Turkey will emerge as the key domestic market in the Middle East and Africa over the coming years, states the research report.

Rising Awareness Pertaining to Ophthalmic Lasers to Fuel Demand

“The increasing prevalence of vision impairment has the most significant influence on demand for ophthalmic laser surgeries,” states a TMR analysts. The incidence of partial as well as complete blindness across the world has been augmenting substantially and is projected to double up by 2020. Cataract, glaucoma, and diabetic retinopathy are the prime cause of blindness in humans and timely medical intervention can avoid these conditions. As ophthalmic laser surgeries provide effective treatment for these conditions, their popularity is rising substantially with the growing awareness about these surgeries among consumers, reflecting greatly on their demand.

For more information on this report, fill the form  @ http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=20864

In addition to this, the technological advancements in ophthalmic lasers are likely to propel this market substantially over the next few years. However, the absence of an appropriate reimbursement scenario in many economies, specifically the emerging ones, may hamper the growth of this market.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Tumor Marker Testing Market - Global Analysis & 2024 Forecast Research Report

A biomarker is any cellular, physical, chemical, or molecular change that can be noted and a normal or abnormal process in human body can be studied. The effects of treatment, the presence, progress or risk for a disease can be checked by studying any alteration in the normal amount of a biomarker. A tumor marker, like a biomarker, is a naturally occurring substance in the body. An increased quantity of a tumor marker can show the presence of a cancer. Some tumor markers are related to several different types of cancer, while some are specific to one type of cancer. Tumor markers may also increase with non-cancerous conditions. A tumor marker can be prepared by cancer cells or by the body in response to cancer.

Obtain Report Details @ http://www.transparencymarketresearch.com/tumor-marker-testing-market.html

There are many different types of tumor markers such as human chorionic gonadotropin (HCG or b-HCG), cancer antigen 15-3 (CA15-3), alpha-fetoprotein (AFP), carbohydrate antigen 19-9 (CA19-9), cancer antigen 125 (CA125), carcinoembryonic antigen (CEA), and prostate-specific antigen (PSA). Tumor markers can provide information that can be used for screening for cancer, diagnose cancer, determine stage of cancer, determine a person’s prognosis, guide treatment, monitor treatment, and determine recurrence of the cancer. Some markers can be used in people with family history of a particular cancer. Prostate specific antigen can be used to screen for prostate cancer. Tumor markers can be used to help determine how far the cancer has spread into other tissues or organs. Some markers are used to determine how aggressive a cancer is likely to be. Some markers may help doctors predict what treatments the cancer is likely to respond to.

A tumor marker test is done to make available a baseline level before treatment, when any type of cancer is suspected, to check if cancer has returned after treatment being given, and to check a person’s reaction to cancer treatment. Tumor markers are molecules found in urine, blood, and body tissues. It is a protein found in large amounts in presence of cancer. Hence, measuring the levels of tumor markers may help in detecting the presence of cancer. Presence of a tumor in body stimulates the production of tumor markers from tumor or non-tumor cells. The tumor marker testing market has been categorized based on diagnostic method, type of cancer, and technology employed for cancer detection. Organ specific tumor marker: bladder, breast, colorectal, gastrointestinal, liver, lung, oral, ovarian, pancreatic, prostatic, skin testicular cancer, leukemia, lymphoma, and others; Clinical laboratory methods for measuring tumor markers: Abbott diagnostics’ AxSYM, Roche Diagnostics System, Fischer Thermo Scientific B.R.A.H.M.S KRYPTOR and others; New technologies for cancer diagnostics: Monoclonal antibodies, proteomics, new protein markers, stem cell markers, DNA microassays and others;  Clinical methods for cancer diagnosis: Screening, imaging, theranostics, sigmoidoscopy and others.

Currently, cancer is the one of the leading causes of death in North America and Europe. North America holds the largest share of the tumor marker testing market, followed by Europe, due to vast discoveries and innovations for detecting cancer in early stages. Major factors driving the tumor marker testing market in these regions are rising incidence of cancer disease, increase in geriatric population, ongoing research in the field of cancer detection, and improved government reimbursement policies. However, high cost acts as a major restraint of the market.

Geographically, North America held the larger market share, followed by Europe. High research on tumor marker and increasing number of cancer patients in these regions are likely to boost the tumor marker testing market. However, affordability has become a restraining factor in this market in developing regions such as Asia Pacific and Latin America. However, the tumor marker testing market in Asia Pacific is expected to experience strong growth.

For more information on this report, fill the form  @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2253

Major players in the tumor marker testing market are Abbott Diagnostics Ltd., Affymetrix, Inc., Agilent Technologies, Inc., Beckman, Dickinson and Company (BD) Diagnostics, BioCurex, BioModa, Inc., Clarient, Inc., Correlogic Systems, Inc., Epigenomics AG, Gen-Probe, Inc., Hologic, Inc., Roche Diagnostics Corp., and Veridex LLC, among others.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Endometriosis Treatment Market: Industry Survey and Industry Outlook 2024

Endometriosis is a medical condition in which the tissue that forms normal lining of uterus appears outside the uterus cavity and may involve ovaries, bowel, or tissue lining of the pelvic floor. This disease affects over 170 million women across the globe. Endometriosis has an unclear etiology and complex symptoms. Hence, the endometriosis treatment market is projected to grow substantially due to increase in number of cases for endometriosis and advancements in treatment technologies. Moreover, growing awareness about endometriosis treatment among women, rising demand for treatment, increasing incidence of endometriosis, and improvement in its diagnosis methods have strengthened the endometriosis treatment market.

Obtain Report Details @ http://www.transparencymarketresearch.com/endometriosis-treatment-market.html

Currently, the endometriosis treatment market is witnessing extensive research and development with significant number of new product introduction. This encourages manufactures to cater to the increasing customer demands. The endometriosis treatment market is consolidated, with top industry players such as AbbVie, Pfizer, Bayer HealthCare, AstraZeneca, and Takeda accounting for majority share. Most of the companies undertake considerable research efforts toward development of novel non-hormonal drugs, diagnostic and surgical techniques, and substantial support in terms of funding. This has fueled the growth of this market. Therefore, significant unmet needs for curative treatment of endometriosis is likely to drive the market. Growth of the global endometriosis market is likely to be driven by emerging economies in Asia, where the disease prevalence is almost 10% of the total female population of this region.

According to the National Center for Biotechnology Information, endometriosis is estimated to affect 10% of women in reproductive age, which increases gradually to 40% in infertility patients. This explains the need of endometriosis treatment in the region, and thereby the potential of endometriosis drugs in the market. Therefore, rising incidence of endometriosis is a major factor driving the endometriosis treatment market in the region. Other factors boosting the endometriosis treatment market include rising demand for advanced endometriosis treatment, intra-industry competition, and increasing new entrants in the market. The endometriosis treatment market is consolidated due to increase in inorganic growth activities such as mergers and acquisitions. However, declining prices due to increasing competition have impacted industry profit margins. Hence, most of the players have adopted the strategy of increasing research activities to develop novel products in the endometriosis treatment market. The endometriosis treatment market has recorded continuous growth in the past few years. Moreover, factors which declining cost of endometriosis treatment, patent loss and increasing number of generic drugs are driving the growth of endometriosis treatment market. Increasing operational costs and rising number of new entrants such as regional and multinational industry players are the key factors hampering the growth of the endometriosis treatment market.

The global endometriosis treatment market has been segmented based on type of product and region. In terms of product, the endometriosis treatment market has been segmented into gonadotrophin releasing hormone agonists (GRH), non-steroidal anti-inflammatory drugs (NSAIDs), progestins, and contraceptive pills. Based on region, the endometriosis treatment market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to account for significant share of the endometriosis treatment market during the forecast period, followed by Europe and Asia Pacific. The market in Asia Pacific is projected to expand at a high CAGR during the forecast period. This report offers an extensive and in-depth assessment of the endometriosis treatment market and also contains situational analysis, facts, insights, historical data, and statistically supported market data validated through industry key opinion leaders. It also offers market estimations with the help of suitable assumptions and methodologies. The market research report contains in-depth analysis and thorough information about market segments such as product type, application, and region.

For more information on this report, fill the form  @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=20834

Key players operating in the global endometriosis treatment market are Abbott Laboratories, Eli Lilly and Company, Meditrina Pharmaceuticals, AstraZeneca plc, Pfizer, Inc., Bayer HealthCare Pharmaceuticals, and Neurocrine Biosciences, Inc.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Personal Dosimeter Market: Segmentation, Global Market Regional Outlook 2024

Personal dosimeter is a sophisticated device that monitors the dose of ionizing radiation and warns with an alarm, once the acceptable dose rate limit is exceeded. The alarm released could be audible or visual or both, depending on the device. A personal dosimeter tracks the changes in exposure and keeps an ongoing record of dose gained by the user over time. It is possible to limit total exposure to radiation and control access to radiological area with its combined access control system. The device is user friendly and allows access to the cumulative radiation dose of the user up to a period of three months. Individuals working in nuclear research facilities, nuclear power plant, and medical laboratories are required to constantly monitor their exposure to harmful radiation, and hence they are the main users of personal dosimeter. The global market for personal dosimeter is growing substantially owing to the rise in demand for these devices as a result of increasing awareness toward the harmful radiation and its ill effects.

Obtain Report Details @ http://www.transparencymarketresearch.com/personal-dosimeter-market.html

The growth of the market for personal dosimeter is driven by its response to harmful radiations and protecting an individual wearing it in any environment. Increase in use of radiation mediated technology and hazardous effects associated with it are projected to contribute to the growth of the global personal dosimeter market. This is attributed to the device’s ability to monitor the radiation. Manufacturers are focused on enhancing the technology and features of the device so as to make it functional in extreme weather conditions and ideal for emergency services, medical services, nuclear and mining environments, and oil and gas industry globally. Furthermore, the ability to monitor the dose captured by smartphones, computers, and tablets features a lucrative market for personal dosimeters worldwide. However, the market growth is restrained by the high cost of the device. In addition, the varying readings due to the effect of electromagnetic fields might impact the accountability of the device, which might be a setback for the market. Furthermore, the device is found to be sensitive to any type of mechanical jerks, leading to false or inaccurate reading. These negative features may hamper the growth of the market considerably.

The global personal dosimeter market can be segmented on the basis of product, end-user, and region. On the basis of product, the market for personal dosimeter can be broadly categorized as non self-reading dosimeter and self-reading dosimeter. Non self-reading dosimeter can be further sub-segmented into film badges, thermoluminescent dosimeter (TLD), and optically stimulated luminescence (OSL) dosimeter. Self-reading dosimeter comprises of electronic dosimeter. On the basis of end-user, the market can be segmented into hospitals, research organizations, and laboratories. The device is mostly used by radiologists, laboratory assistants, medical personnel, and patients.

Geographically, the global market can be distributed over North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the market owing to high awareness toward the health hazards caused by the harmful radiations and increase in number of skin disorders such as cancer. Europe is gaining a strong position in the market with increase in government initiatives and stringent regulations toward harmful radiation hazards. The Asia market is expected to grow during the forecast period with the increasing use of radiation in medical fields and nuclear plants, and growing awareness about the preventive measures, along with advanced technology.

For more information on this report, fill the form  @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=20798

Key players operating in the market include Landauer, Thermo Fisher Scientific Inc., Mirion Technologies, Inc., Radiation Detection Company Inc., ATOMTEX, Panasonic Corporation, Ludlum Measurements, Inc., Fluke Corporation, Fuji Electric Co., Ltd., and Biodex Medical Systems, Inc.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Latest Research Report on Cone Beam Imaging Market: Trends and Opportunities 2024

Cone beam imaging is a novel technology which has been revolutionizing diagnostic procedures and treatment monitoring in dentistry and maxillofacial surgeries. A cone beam imaging system is typically a digital X-ray scanner which is fixed on a 360-degree rotating arm. The cone-beam machine emits an X-ray beam shaped like a cone instead of a fan as in a traditional computed tomography (CT) machine. The effective dose from cone-beam imaging ranges from 6 to 477 microSv.

Obtain Report Details @ http://www.transparencymarketresearch.com/cone-beam-imaging-market.html

Various factors are likely to propel the market for cone beam imaging during the forecast period. Rise in preference of surgeons and dentists to provide superior patient comfort coupled with enhancement in patient safety is boosting the market sales of the cone beam imaging systems. A cone beam system is used with ease by just requiring the patient to sit on a chair while the scanner moves in one complete circle around the head, gathering all the scan data needed. The system eliminates the necessity of any special preparation. The procedure provides the doctor (surgeon/specialist/dentist) with images in various angles and studies of the interrelation between teeth, bones, nerves, and tissues. It allows the doctor to evaluate the patient’s condition with comprehensive data, and thus plan out the most effective treatment. Moreover, while cone beam imaging produces the same kind of superior images similar to a CT scan, it does so with less radiation. Furthermore, the technology is easy to learn and the software applications accessible for dentistry are widespread. Thus, these advantages are anticipated to move the market toward positive strides. However, the penetration of these systems in smaller private clinics may be a challenge due to higher cost considerations.

The cone beam imaging market has been segmented on the basis of product type, indication, end-user, and geography. On the basis of product type, the market has been segmented into patient standing and patient seated variants. Based on indication, the market has been segmented into dentistry and maxillofacial surgery. In dentistry, the most common indications for cone beam imaging are periodontics, endodontics, orthodontics, and dental implants. This includes techniques such as examining the teeth and facial structures for orthodontic treatment planning, evaluating the jaws for placing dental implants, assessing the temporomandibular joints for figuring degenerative changes, evaluating the closeness of lower wisdom teeth to the mandibular nerve before its extraction procedure, and examining teeth and bone for signs of cysts, infections, or tumors. Conventional tomography has been widely replaced by cone beam images for these factors. Based on end-user, the market has been segmented into specialty clinics and hospitals.

Geographically, the market is segmented into the following regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe are anticipated to garner higher shares in the cone beam imaging market owing to high adoption of leading edge technologies. Moreover, the dental specialty clinics and hospitals in these regions have the capital to switch to such systems compared to their counterparts in emerging economies. According to the American Academy of Implant Dentistry, approximately 3 million U.S. citizens have implants and that number is growing by nearly 500,000 per year. In addition, the adoption rate of cone beam imaging systems is fairly high in the U.S. Thus, the cone beam imaging market in North America is projected a promising growth during the forecast period. Dental treatment is relatively much cheaper in countries such as India and Brazil, and thus these countries act as a medical tourism hub for dental procedures. To make medical tourism more patient friendly, leading end-users may adopt to cone beam imaging technologies in Asia Pacific and Latin America during the forecast period. These regions thus plausibly represent the most attractive markets for key players to invest during the next seven to eight years.

For more information on this report, fill the form  @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=20756

The key players operating in the market include Biolase, Inc., Ray Medical Co., Ltd, Sirona Dental Systems, Gendex Dental Systems, Carestream, Imaging Sciences International, LLC, Prexion, Inc., Planmeca USA, Inc., and Genoray America Inc.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Enteral Stents Market Trends and Growth Drivers Analysis 2024

Enteral stents maintain the lumen of hollow organs, vessels, and ducts. These stents are used for the treatment of palliation of malignant obstruction as well as treatment of malignant luminal obstruction of the gastrointestinal tract. Enteral stents are also used within the colon as a pre-operative modality. Technological advancements have led to development of several types of flexible and self-expandable stents with greater success rates. Currently available enteral stents include self-expandable metal stents (SEMS) for esophageal, gastroduodenal, and malignant colon obstruction and self-expandable plastic stents (SEPS) for malignant or benign esophageal strictures. Self-expandable metal stents (SEMS) are composed of a variety of metal alloys and are of varying sizes and shapes depending on the individual manufacturer and organ of placement. Enteral stents are available as fully covered, uncovered, or partially covered varieties, with the coating usually being a plastic membrane or silicone. Each of these stent types has its own inherent advantages and disadvantages and optimal uses in clinical practice. Colorectal cancer that produces left-sided colonic obstruction is the most common indication for placement of self- metastatic expandable metal stents for pre-operative decompression. Colorectal stent placement may serve as a palliative modality of obstruction when patients with primary or recurrent colorectal carcinoma where the disease is widely metastatic. Cancer is often considered a disease of affluence, but about 70% of cancer deaths occur in low- and middle-income countries.

Obtain Report Details @ http://www.transparencymarketresearch.com/enteral-stents-market.html

New product innovation, increasing prevalence of cancer disease, rapidly growing population, and changing lifestyles are projected to drive the global enteral stents market. Technological advancement and rising adoption of enteral stents are other factors expected to fuel the growth of the global enteral stents market. On the other hand, adverse effects of products are likely to hamper the growth of the enteral stents market.

The enteral stents market has been segmented based on stent type, product type, end-user, and region. In terms of stent type, the enteral stents market has been classified into esophageal stents, gastroduodenal stents, and colon stents. There are two types of placement of colonic stents for relief of colonic obstruction: pre-operative decompression and palliation of advanced malignancy. In terms of product type, the market has been categorized into self-expandable metal stents (SEMS) and self-expandable plastic stents (SEPS). Self-expandable metal stents (SEMS) have been classified into uncovered SEMS, partially covered SEMS, and fully covered SEMS. In terms of end-user, the enteral stents market has been classified into hospitals, specialty clinics, ambulatory centers, and research centers.

Geographically, the enteral stents market has been segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

North America dominates the enteral stents market due to technological advancement, lifestyle change, growing prevalence of cancer, and early treatment adoption. According to the National Cancer Institute (2014), the number of people living with cancer reached 14.5 million and is expected to increase to 19 million by 2024. Europe is the second largest market for enteral stents. Asia Pacific is expected to grow at higher rate due to increasing per capita expenditure, developing health care infrastructure, rapid population growth, and increasing research and development. Latin America and Middle East & Africa will create a significant opportunity for the persistent facial erythema treatment market due to increasing consumption of alcohol, private and government health care insurance coverage, growing awareness among people, and increasing investment of key manufacturers in this area. According to global cancer’s foot print, In Brazil cancer cases annually is 171.3 per 1000,000 people.

Major players operating in the enteral stents market include Boston Scientific Corporation, Cook Medical, Abbott Vascular, Biosensors International, Stryker Corporation, Medtronic, Inc., B. Braun Melsungen AG, C. R. Bard, Cordis Corporation, and Terumo Corporation, among others.

For more information on this report, fill the form  @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=20708

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/